Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX

OBJECTIVES: Neoadjuvant therapy (NT) is used for advanced pancreatic ductal adenocarcinoma (PDAC). No clear guidelines exist for switching therapies when patients do not respond to initial NT. We sought to characterize patients who underwent early switch from FOLFIRINOX to gemcitabine/nab-paclitaxel...

全面介紹

Na minha lista:
書目詳細資料
發表在:Pancreas
Main Authors: Vreeland, Timothy J, McAllister, Florencia, Javadi, Sanaz, Prakash, Laura R., Fogelman, David R., Ho, Linus, Varadhachary, Gauri, Aloia, Thomas A., Vauthey, Jean-Nicolas, Lee, Jeffrey E., Kim, Michael, Katz, Matthew H.G., Tzeng, Ching-Wei D.
格式: Artigo
語言:Inglês
出版: 2019
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7309587/
https://ncbi.nlm.nih.gov/pubmed/31210666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MPA.0000000000001345
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍